Abstract
Leiomyosarcoma (LMS) is an aggressive mesenchymal malignancy with few therapeutic options. The mechanisms underlying LMS development, including clinically actionable genetic vulnerabilities, are largely unknown. Here we show, using whole-exome and transcriptome sequencing, that LMS tumors are characterized by substantial mutational heterogeneity, near-universal inactivation of TP53 and RB1, widespread DNA copy number alterations including chromothripsis, and frequent whole-genome duplication. Furthermore, we detect alternative telomere lengthening in 78% of cases and identify recurrent alterations in telomere maintenance genes such as ATRX, RBL2, and SP100, providing insight into the genetic basis of this mechanism. Finally, most tumors display hallmarks of "BRCAness", including alterations in homologous recombination DNA repair genes, multiple structural rearrangements, and enrichment of specific mutational signatures, and cultured LMS cells are sensitive towards olaparib and cisplatin. This comprehensive study of LMS genomics has uncovered key biological features that may inform future experimental research and enable the design of novel therapies.
Introduction
Leiomyosarcoma (LMS) is an aggressive cancer of smooth muscle origin with a dismal prognosis once it metastasizes, with median survival rates of roughly 12 months. Historically, LMS has been a "black box" for precision medicine due to a lack of clear, single-driver mutations. While older cytogenetic studies described LMS as having "chaotic" genomes, high-resolution mapping of specific genetic vulnerabilities was needed to move beyond simple descriptions of chromosomal messiness to find actionable biological patterns.
Methods
The researchers performed an integrative analysis on a cohort of 49 adult LMS patients (39 non-uterine, 10 uterine) using:
- Whole-Exome Sequencing (WES): To identify somatic mutations (SNVs and indels) and copy-number alterations (CNAs).
- Transcriptome Sequencing (RNA-seq): To analyze gene expression profiles and identify high-confidence fusion transcripts.
- C-circle Assays: A specialized biochemical test to detect Alternative Lengthening of Telomeres (ALT).
- Bioinformatics Pipelines: Tools like MutSigCV for identifying driver genes and HotNet2 for gene network analysis.
- Functional Validation: Testing the "BRCAness" hypothesis using clonogenic assays on LMS cell lines treated with the PARP inhibitor olaparib and cisplatin.
Key Results and Insights
The Genomic Landscape of LMS
The study revealed that while LMS has a moderate mutation rate, it is defined by extreme structural complexity. A unifying feature discovered is the near-universal biallelic inactivation of TP53 and RB1. Integrating mutations, deletions, and fusions, over 90% of cases showed inactivation of both genes, suggesting this loss is the foundational event in LMS development.
Network analysis further underscored the central role of these tumor suppressors, identifying them as major hubs in the LMS mutational landscape, often interacting with other recurrently altered genes like PTEN.
ALT Dominance and Genomic Instability
The genomic "chaos" in LMS is often the result of chromothripsis and whole-genome duplication (WGD), the latter occurring in 55% of cases. Notably, 78% of LMS tumors use Alternative Lengthening of Telomeres (ALT) to achieve immortality—the highest frequency reported for any tumor type. The study identified RBL2 and SP100 as novel candidate drivers of this process.
The "BRCAness" Signature and Therapeutic Potential
Most LMS tumors display a "BRCAness" genomic signature, characterized by specific mutational scars and structural rearrangements typical of homologous recombination repair (HRR) deficiency. In vitro testing showed that LMS cell lines were highly sensitive to the PARP inhibitor olaparib, with enhanced effects when combined with cisplatin. This provides a strong preclinical rationale for repositioning these drugs for LMS patients.
Limitations and Future Work
While comprehensive, the study's cohort size (49 patients) means larger studies are needed to further distinguish uterine and non-uterine LMS biology. Additionally, the authors emphasize that genomics-guided clinical trials are the necessary next step to determine if the observed "BRCAness" phenotype translates to real-world patient responses.
Summary updated